



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/897,844	07/02/2001	George Norbert Cox III	8325-0002.01	2083
42997 7590 09/11/2007 SANGAMO BIOSCIENCES, INC. 501 CANAL BOULEVARD, SUITE A100 RICHMOND, CA 94804			EXAMINER BRUSCA, JOHN S	
			ART UNIT 1631	PAPER NUMBER
			MAIL DATE 09/11/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
09897844	7/2/2001	COX ET AL.	8325-0002.01

SANGAMO BIOSCIENCES, INC.  
501 CANAL BOULEVARD, SUITE A100  
RICHMOND, CA 94804

EXAMINER

John S.. Brusca

ART UNIT	PAPER
----------	-------

1631

20070904


DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner for Patents

The Office has determined a number of typographical errors introduced by Office error after allowance of Application No. 09/897844 (issued as U.S. Patent No. 6,979,539). The Office is requesting a Certificate of Correction under 35 U.S.C. 254 and 37 CFR 1.322 to correct an Office mistake. The Certificate of Correction Branch will be notified of this request.

The corrections are attached to this form.

  
RAM R. SHUKLA, PH.D.  
SUPERVISORY PATENT EXAMINER

/John S. Brusca/  
Primary Examiner  
Art Unit: 1631

Art Unit: 1631

Office initiated Certificate of Correction Memo

The following claims are corrected as follows (formatted by strikethrough of deleted text and underlining added text)

1. A method of inhibiting expression of an endogenous cellular ~~pine~~ gene in a cell, the method comprising the step of:

administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein

(i) said polynucleotide sequence is operably linked to a promoter,

(ii) the nucleic acid molecule expresses the zinc finger protein ~~is less~~ in the cell;

(iii) the zinc finger protein contacts a first target site in the endogenous cellular gene; and

(iv) the K<sub>sub.d</sub> of the zinc finger protein is less than about 25 nM;

thereby inhibiting expression of the endogenous cellular gene.

2. The method of claim 1 wherein the step of administering further comprises

administering a second zinc finger protein-encoding nucleic acid operably

linked to a promoter that expresses a second zinc finger protein in the cell,

and wherein the ~~step~~ step of contacting ~~father~~ further comprises contacting a second target

site in the endogenous cellular gene with the second zinc finger protein.

3. The method claim 2, wherein the ~~flat was~~ first and second target sites are

Art Unit: 1631

adjacent.

4. The method ~~or of~~ of claim 3, wherein the first and second zinc finger proteins are covalently linked, ~~miming~~ forming a fusion protein.

16. The method of claim 1, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a lipid:nucleic acid complex or as naked nucleic acid.

18. The method of claim ~~4~~ 17, wherein the expression vector is a viral expression vector.

19. The method of claim 18, wherein the expression vector is a retroviral expression vector, an ~~adenoviral~~ adenoviral expression vector, or an AAV expression vector.

20. The method of claim 18 wherein the promoter to which the zinc finger-encoding nucleic acid is operably linked is an ~~inductable~~ inducible promoter.

29. A method of inhibiting expression of an endogenous cellular ~~gene~~ gene in a cell, the method comprising the step of: administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein

Art Unit: 1631

- (i) said polynucleotide sequence is operably linked to a promoter;
  - (ii) the nucleic acid molecule expresses the zinc finger protein in the cell;
  - (iii) the fusion zinc finger protein comprises six fingers and a regulatory domain;
  - (iv) the fusion zinc finger protein contacts a target site in the endogenous cellular gene and;
  - (v) the  $K_d$  of the zinc finger protein is less than about 25 nM;
- thereby inhibiting expression of the endogenous cellular gene.

31. The method of claim 30, wherein the step of administering ~~father~~ further comprises administering a second zinc finger protein-encoding nucleic add operably linked to a promoter that expresses a second zinc finger protein in the cell and wherein the step of contacting further comprises contacting a second target site ~~ix~~ in the endogenous cellular gene with the second zinc finger protein.

45. The method of claim 30, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a lipid:nucleic acid complex or as ~~marked~~ naked nucleic acid.

46. The method of claim 30, wherein the nucleic acid molecule is an expression vector comprising a zinc finger protein encoding nucleic acid operably linked toe a promoter.

Art Unit: 1631

49. The method of claim 47, wherein the promoter to which the zinc finger ~~protein encoding by a nucleic acid~~ is operably linked to an inducible promoter.

50. The method of claim 47, wherein the promoter to which the zinc finger ~~protein encoding by a nucleic acid~~ is operably linked is a weak promoter.

54. The method of claim ~~31~~ 30, wherein the target site is adjacent to an RNA polymerase pause site, wherein the RNA polymerase pause site is downstream of a transcription initiation site of the endogenous cellular gene.

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.:** 6,979,539

Page 2 of 2

**DATED:** July 04, 2006

**INVENTOR(S):** George Norbert Cox III; Casey Christopher Case; Stephen P. Eisenberg; Eric Edward Jarvis; Sharon Kaye Spratt

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.:** 6,979,539

Page 1 of 2

**DATED:** July 04, 2006

**INVENTOR(S):** George Norbert Cox III; Casey Christopher Case; Stephen P. Eisenberg; Eric Edward Jarvis; Sharon Kaye Spratt

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claims have been rewritten as follows:

1. A method of inhibiting expression of an endogenous cellular pine gene in a cell, the method comprising the step of:  
administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein
  - (i) said polynucleotide sequence is operably linked to a promoter,
  - (ii) the nucleic acid molecule expresses the zinc finger protein is less in the cell;
  - (iii) the zinc finger protein contacts a first target site in the endogenous cellular gene; and
  - (iv) the K.sub.d of the zinc finger protein is less than about 25 nM;thereby inhibiting expression of the endogenous cellular gene.
2. The method of claim 1 wherein the step of administering further comprises administering a second zinc finger protein-encoding nucleic acid operably linked to a promoter that expresses a second zinc finger protein in the cell, and wherein the stop step of contacting father further comprises contacting a second target site in the endogenous cellular gene with the second zinc finger protein.
3. The method claim 2, wherein the flat wad first and second target sites are adjacent.
4. The method or of claim 3, wherein the first and second zinc finger proteins are covalently linked, miming forming a fusion protein.
16. The method of claim 1, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a



**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.:** 6,979,539

Page 2 of 2

**DATED:** July 04, 2006

**INVENTOR(S):** George Norbert Cox III; Casey Christopher Case; Stephen P. Eisenberg; Eric Edward Jarvis; Sharon Kaye Spratt

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

lipid:nucleic acid complex or as naked nucleic acid.

18. The method of claim 17, wherein the expression vector is a viral expression vector.

19. The method of claim 18, wherein the expression vector is a retroviral expression vector, an adenoviral expression vector, or an AAV expression vector.

20. The method of claim 18 wherein the promoter to which the zinc finger-encoding nucleic acid is operably linked is an inductable inducible promoter.

29. A method of inhibiting expression of an endogenous cellular gene in a cell, the method comprising the step of: administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein  
(i) said polynucleotide sequence is operably linked to a promoter;  
(ii) the nucleic acid molecule expresses the zinc finger protein in the cell;  
(iii) the fusion zinc finger protein comprises six fingers and a regulatory domain;  
(iv) the fusion zinc finger protein contacts a target site in the endogenous cellular gene and;  
(v) the K<sub>d</sub> of the zinc finger protein is less than about 25 nM;  
thereby inhibiting expression of the endogenous cellular gene.

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO.:** 6,979,539

Page 1 of 2

**DATED:** July 04, 2006

**INVENTOR(S):** George Norbert Cox III; Casey Christopher Case; Stephen P. Eisenberg; Eric Edward Jarvis; Sharon Kaye Spratt

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claims have been rewritten as follows:

31. The method of claim 30, wherein the step of administering further comprises administering a second zinc finger protein-encoding nucleic acid operably linked to a promoter that expresses a second zinc finger protein in the cell and wherein the step of contacting further comprises contacting a second target site in the endogenous cellular gene with the second zinc finger protein.
45. The method of claim 30, wherein the step of administering the nucleic acid molecule to the cell comprises administering the nucleic acid molecule in a lipid:nucleic acid complex or as marked naked nucleic acid.
46. The method of claim 30, wherein the nucleic acid molecule is an expression vector comprising a zinc finger protein encoding nucleic acid operably linked to a promoter.
49. The method of claim 47, wherein the promoter to which the zinc finger protein encoding by a nucleic acid is operably linked to an inducible promoter.
50. The method of claim 47, wherein the promoter to which the zinc finger protein encoding by a nucleic acid is operably linked is a weak promoter.
54. The method of claim 31, wherein the target site is adjacent to an RNA polymerase pause site, wherein the RNA polymerase pause site is downstream of a transcription initiation site of the endogenous cellular gene.